Brokerages predict that VERONA PHARMA P/S (NASDAQ:VRNA) will post earnings of ($0.61) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for VERONA PHARMA P/S’s earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.50). VERONA PHARMA P/S posted earnings of $0.06 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1,116.7%. The business is expected to issue its next quarterly earnings report on Tuesday, August 6th.
Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.04.
VRNA has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of VERONA PHARMA P/S from a “buy” rating to a “hold” rating and set a $7.25 price objective on the stock. in a report on Saturday, April 27th. BTIG Research initiated coverage on shares of VERONA PHARMA P/S in a report on Wednesday, April 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $58.00 price objective (up from $56.00) on shares of VERONA PHARMA P/S in a report on Monday, May 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $27.00.
VERONA PHARMA P/S stock traded down $0.22 during midday trading on Tuesday, hitting $5.92. 5,206 shares of the stock were exchanged, compared to its average volume of 5,551. VERONA PHARMA P/S has a 52 week low of $5.52 and a 52 week high of $17.16. The firm has a market capitalization of $77.94 million, a price-to-earnings ratio of -2.93 and a beta of -1.14.
Several hedge funds and other institutional investors have recently bought and sold shares of VRNA. Wedbush Securities Inc. acquired a new position in shares of VERONA PHARMA P/S in the fourth quarter valued at $127,000. Aisling Capital Management LP acquired a new position in shares of VERONA PHARMA P/S in the fourth quarter valued at $4,281,000. venBio Partners LLC bought a new stake in shares of VERONA PHARMA P/S in the first quarter valued at about $5,688,000. IHT Wealth Management LLC bought a new stake in shares of VERONA PHARMA P/S in the first quarter valued at about $113,000. Finally, Renaissance Technologies LLC bought a new stake in shares of VERONA PHARMA P/S in the first quarter valued at about $76,000. Institutional investors own 57.49% of the company’s stock.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Featured Article: Channel Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.